Cardiovascular disease (CVD) remains a leading cause of death in the United States. Statin therapy has proven remarkably effective in reducing CVD events when used in those at risk, yet statins remain under- utilized. These gaps in care represent a twofold problem: a failure to appropriately identify candidates for primary prevention and a failure of patients to take these medications when offered. Currently available models to predict CVD risk have significant limitations, particularly for younger adults. Further, their probabilistic outputs are neither easily understood nor impactful to patients. Dr. Navar's K01 proposal uses pooled data from seven NHLBI cohort studies to create an improved CVD risk prediction model for young adults. This model will estimate ?continuous? lifetime CVD risk, incorporating a range of risk factors and evaluating risk at multiple patient ages. Second, Dr. Navar will evaluate how this novel continuous lifetime risk model improves identification of candidates for statin therapy relative to current risk tools. Third, to improve the ability to communicate these data to patients, she will transform these risk estimates into population relative risk. This will allow a patient to understand how his CVD risk profile compares with similar age- and gender-matched peers. She will then use a unique national registry to better understand how best to communicate numerical and probabilistic data to which patients. Finally, she will develop a web-based risk communication tool that incorporates the novel lifetime risk, population relative risk, and current 10-year risk estimates and pilot this tool in patient focus groups. This web-based tool will be linked to the electronic health record and tested in an outpatient clinical setting to assess how real time estimation and patient-tailored shared decision-making affect clinical care. The current proposal will also assist Dr. Navar in fully strengthening her background in public health. The didactic and applied statistical experiences, including training in predictive modeling and causal analysis, will allow her to become more prepared to be a national leader in the understanding of real world safety and effectiveness of preventive therapies. Similarly, the formal training in qualitative research and behavioral science proposed in this application, combined with the practical development of a CVD risk communication tool, will allow her to establish a program of independent research focused on improved uptake of CVD preventive therapies through effective patient risk communication. This training program builds on already successful research at the Duke Clinical Research Institute (DCRI). The mentorship team, led by Dr. Eric Peterson, Director of the DCRI and expert in CVD outcomes research, includes experts in risk prediction (Pencina, co-mentor, and D'Agostino, external advisor) and risk communication (Boulware, co-mentor), all of whom will ensure scientific success and oversee the candidate's advanced training in their relative areas of expertise. By the conclusion of this program, Dr. Navar will be able to carry out advanced research in CVD prevention as an independent physician-scientist.

Public Health Relevance

Although cardiovascular disease is the leading cause of death in the U.S., uptake of preventive therapies is poor, and current statin guidelines fail to identify many young adults for statins prior to development of CVD. This proposal will improve identification of high-risk young adults by creating a new model for lifetime risk estimation and evaluating the potential impact of this model if applied to statin guidelines. To improve uptake of statin therapy in young adults through shared decision making, we will then translate this risk into a population relative risk, create and test a web-based, personalized tool for CVD risk communication that includes lifetime and population relative risks, and integrate this tool into the clinic visit by linking it to the electronic health record in real time.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01HL133416-05
Application #
9982377
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Hsu, Lucy L
Project Start
2016-08-15
Project End
2021-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Hess, Paul L; Kennedy, Kevin; Cowherd, Michael et al. (2018) Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. Am Heart J 195:151-152
Navar, Ann Marie; Pencina, Michael J; Mulder, Hillary et al. (2018) Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles. Am Heart J 198:18-24
Fanaroff, Alexander C; Li, Shuang; Webb, Laura E et al. (2018) An Observational Study of the Association of Video- Versus Text-Based Informed Consent With Multicenter Trial Enrollment: Lessons From the PALM Study (Patient and Provider Assessment of Lipid Management). Circ Cardiovasc Qual Outcomes 11:e004675
Clement, Meredith E; Lin, Li; Navar, Ann Marie et al. (2018) Lower likelihood of cardiac procedures after acute coronary syndrome in patients with human immunodeficiency virus/acquired immunodeficiency syndrome. Medicine (Baltimore) 97:e9849
Navar, Ann Marie; Peterson, Eric D; Li, Shuang et al. (2018) Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice: Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry. Circ Cardiovasc Qual Outcomes 11:e004249
Navar, Ann Marie; Peterson, Eric D (2018) Challenges in Interpreting the Lipid-Lowering Trials: Biology vs Ecology. JAMA 319:1549-1551
Pagidipati, Neha J; Navar, Ann Marie; Pieper, Karen S et al. (2017) Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). Circulation 136:1193-1203
Navar, Ann Marie; Peterson, Eric (2017) The Complexities of Hypertension: One Disease or Many? JAMA Cardiol 2:389-390
Navar, Ann Marie; Taylor, Benjamin; Mulder, Hillary et al. (2017) Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy. JAMA Cardiol 2:1217-1225
Pagidipati, Neha J; Navar, Ann Marie; Mulder, Hillary et al. (2017) Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. JAMA 317:1563-1567

Showing the most recent 10 out of 17 publications